OBJECTIVES: To determine the prevalence of antibodies to the human T cell leukaemia/lymphoma viruses (HTLV-I and HTLV-II) in blood donors in north London in order to assess the economic impact and the logistic effects that routine screening would have on the blood supply. DESIGN: All donations collected by the north London blood transfusion centre between January 1991 and June 1991 were screened for antibodies to HTLV-I and HTLV-II by modified, improved Fujirebio gel particle agglutination test. Positive samples were titrated and retested as necessary. SUBJECTS: 96,720 unpaid volunteers, who gave 105,730 consecutive donations of blood and plasma. SETTING: North London blood transfusion centre. MAIN OUTCOME MEASURE: Observed numbers of donors confirmed to be seropositive for HTLV by reference laboratories. RESULTS: Of 2622 (2.5%) initially reactive samples, 414 (0.4% of all samples) gave a titre of > or = 1 in 16 on the modified agglutination test. Thirty five of the 414 serum samples yielded positive results on one of two enzyme linked immunosorbent assays (ELISA (Cambridge Biotech and Abbot)), and none of these results were confirmed by either reference laboratory. Five samples yielded positive results on both ELISAs and all five of these were confirmed to contain antibodies to HTLV. One of the five contained antibodies to HTLV-II and the others antibodies to HTLV-I. Four seropositive donors were white women whose only risk factor for infection was sexual contact. The fifth (positive for antibodies to HTLV-II) was an Anglo-Caribbean man who admitted to previous misuse of intravenous drugs. CONCLUSION: The prevalence of antibodies to HTLV in blood donors in north London was one in 19,344 (0.005%). Up to 100 donors a year might be identified in the United Kingdom as being infected with HTLV, although prevalence in different regions may vary considerably.
OBJECTIVES: To determine the prevalence of antibodies to the human T cell leukaemia/lymphoma viruses (HTLV-I and HTLV-II) in blood donors in north London in order to assess the economic impact and the logistic effects that routine screening would have on the blood supply. DESIGN: All donations collected by the north London blood transfusion centre between January 1991 and June 1991 were screened for antibodies to HTLV-I and HTLV-II by modified, improved Fujirebio gel particle agglutination test. Positive samples were titrated and retested as necessary. SUBJECTS: 96,720 unpaid volunteers, who gave 105,730 consecutive donations of blood and plasma. SETTING: North London blood transfusion centre. MAIN OUTCOME MEASURE: Observed numbers of donors confirmed to be seropositive for HTLV by reference laboratories. RESULTS: Of 2622 (2.5%) initially reactive samples, 414 (0.4% of all samples) gave a titre of > or = 1 in 16 on the modified agglutination test. Thirty five of the 414 serum samples yielded positive results on one of two enzyme linked immunosorbent assays (ELISA (Cambridge Biotech and Abbot)), and none of these results were confirmed by either reference laboratory. Five samples yielded positive results on both ELISAs and all five of these were confirmed to contain antibodies to HTLV. One of the five contained antibodies to HTLV-II and the others antibodies to HTLV-I. Four seropositive donors were white women whose only risk factor for infection was sexual contact. The fifth (positive for antibodies to HTLV-II) was an Anglo-Caribbean man who admitted to previous misuse of intravenous drugs. CONCLUSION: The prevalence of antibodies to HTLV in blood donors in north London was one in 19,344 (0.005%). Up to 100 donors a year might be identified in the United Kingdom as being infected with HTLV, although prevalence in different regions may vary considerably.
Authors: R Salker; J H Tosswill; J A Barbara; J Runganga; M Contreras; R S Tedder; N Parra-Mejia; P P Mortimer Journal: Lancet Date: 1990-08-04 Impact factor: 79.321
Authors: E L Murphy; B Hanchard; J P Figueroa; W N Gibbs; W S Lofters; M Campbell; J J Goedert; W A Blattner Journal: Int J Cancer Date: 1989-02-15 Impact factor: 7.396
Authors: Y C Chen; C H Wang; I J Su; C Y Hu; M J Chou; T H Lee; D T Lin; T Y Chung; C H Liu; C S Yang Journal: Blood Date: 1989-07 Impact factor: 22.113
Authors: G Y Minamoto; J W Gold; D A Scheinberg; W D Hardy; N Chein; E Zuckerman; L Reich; K Dietz; T Gee; J Hoffer Journal: N Engl J Med Date: 1988-01-28 Impact factor: 91.245
Authors: E Tynell; S Andersson; E Lithander; M Arneborn; J Blomberg; H B Hansson; A Krook; M Nomberg; K Ramstedt; A Shanwell; A Bjorkman Journal: BMJ Date: 1998-05-09
Authors: E J Calderón; C Rey; F J Medrano; J Sánchez-Román; V Soriano; Y Torres; M Ruiz; E Lissen; M Leal Journal: Eur J Clin Microbiol Infect Dis Date: 1995-08 Impact factor: 3.267